Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Sarcoma 2Vulvar Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 2Observation 2Leucovorin 2Irinotecan 2Ipilimumab 2Cisplatin 2tivozanib 1spartalizumab 1seribantumab 1pembrolizumab 1motexafin lutetium 1entinostat 1atezolizumab 1Thalidomide 1Specimen Handling 1Quality of Life 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Paclitaxel 1Octreotide 1Nivolumab 1Molecular Diagnostic Techniques 1Mesna 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Ifosfamide 1Fluorouracil 1Floxuridine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × tivozanib × Sarcoma × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡